Cholate-modified polymer-lipid hybrid nanoparticles for oral delivery of quercetin to potentiate the antileukemic effect

References

• Anand David AV, Arulmoli R, Parasuraman S. Overviews of biological importance of quercetin: a bioactive flavonoid. Pharmacogn Rev. 2016;10(20):84–89. doi:10.4103/0973-7847.19404428082789
   PubMedGoogle Scholar
• Baron BW, Thirman MJ, Giurcanu MC, Baron JM. Quercetin therapy for selected patients with PIM1 kinase-positive chronic lymphocytic leukemia/small lymphocytic lymphoma: a pilot study. Acta Haematol. 2018;139(2):132–139. doi:10.1159/00048636129444501
   PubMedGoogle Scholar
• Calgarotto AK, Maso V, Junior GCF, et al. Antitumor activities of Quercetin and Green Tea in xenografts of human leukemia HL60 cells. Sci Rep. 2018;8(1):3459. doi:10.1038/s41598-018-21516-529472583
   PubMed Web of Science ®Google Scholar
• Naimi A, Entezari A, Hagh MF, Hassanzadeh A, Saraei R, Solali S. Quercetin sensitizes human myeloid leukemia KG-1 cells against TRAIL-induced apoptosis. J Cell Physiol. 2019;234(8):13233–13241. doi: 10.1002/jcp.27995
   Google Scholar
• Rich GT, Buchweitz M, Winterbone MS, Kroon PA, Wilde PJ. Towards an understanding of the low bioavailability of quercetin: a study of its interaction with intestinal lipids. Nutrients. 2017;9(2):111. doi:10.3390/nu9020111
   PubMed Web of Science ®Google Scholar
• Barbosa AI, Costa Lima SA, Reis S. Application of pH-responsive fucoidan/chitosan nanoparticles to improve oral quercetin delivery. Molecules. 2019;24(2):346. doi:10.3390/molecules24020346
   PubMed Web of Science ®Google Scholar
• Dian L, Yu E, Chen X, et al. Enhancing oral bioavailability of quercetin using novel soluplus polymeric micelles. Nanoscale Res Lett. 2014;9(1):2406. doi:10.1186/1556-276X-9-68426088982
   PubMedGoogle Scholar
• Zhang K, Zhang M, Liu Z, et al. Development of quercetin-phospholipid complex to improve the bioavailability and protection effects against carbon tetrachloride-induced hepatotoxicity in SD rats. Fitoterapia. 2016;113:102–109. doi:10.1016/j.fitote.2016.07.008.26718734
   PubMedGoogle Scholar
• Ghaffari F, Hajizadeh Moghaddam A, Zare M. Neuroprotective effect of quercetin nanocrystal in a 6-hydroxydopamine model of parkinson disease: biochemical and behavioral evidence. Basic Clin Neurosci. 2018;9(5):317–324. doi:10.32598/bcn.9.5.31730719246
   PubMed Web of Science ®Google Scholar
• Zhang X, Xing H, Zhao Y, Ma Z. Pharmaceutical dispersion techniques for dissolution and bioavailability enhancement of poorly water-soluble drugs. Pharmaceutics. 2018;10(3):74. doi:10.3390/pharmaceutics10030074
   PubMed Web of Science ®Google Scholar
• Li Q, Cai T, Huang Y, Xia X, Cole S, Cai Y. A review of the structure, preparation, and application of NLCs, PNPs, and PLNs. Nanomaterials. 2017;7(6):122. doi:10.3390/nano7120458
   Web of Science ®Google Scholar
• Pandita D, Kumar S, Lather V. Hybrid poly (lactic-co-glycolic acid) nanoparticles: design and delivery prospectives. Drug Discov Today. 2015;20(1):95–104. doi:10.1016/j.drudis.2014.09.01825277320
   PubMed Web of Science ®Google Scholar
• Grigoras AG. Polymer-lipid hybrid systems used as carriers for insulin delivery. Nanomedicine. 2017;13(8):2425–2437. doi:10.1016/j.nano.2017.08.00528821465
   PubMed Web of Science ®Google Scholar
• Bose RJC, Ravikumar R, Karuppagounder V, Bennet D, Rangasamy S, Thandavarayan RA. Lipid-polymer hybrid nanoparticle-mediated therapeutics delivery: advances and challenges. Drug Discov Today. 2017;22(8):1258–1265. doi:10.1016/j.drudis.2017.05.01528600191
   PubMed Web of Science ®Google Scholar
• Jose C, Amra K, Bhavsar C, Momin M, Omri A. Polymeric lipid hybrid nanoparticles: properties and therapeutic applications. Crit Rev Ther Drug Carrier Syst. 2018;35(6):555–588. doi:10.1615/CritRevTherDrugCarrierSyst.201802475130317969
   PubMedGoogle Scholar
• Xiao L, Pan G. An important intestinal transporter that regulates the enterohepatic circulation of bile acids and cholesterol homeostasis: the apical sodium-dependent bile acid transporter (SLC10A2/ASBT). Clin Res Hepatol Gastroenterol. 2017;41(5):509–515. doi:10.1016/j.clinre.2017.02.00128336180
   PubMed Web of Science ®Google Scholar
• Khatun Z, Nurunnabi M, Cho KJ, Byun Y, Bae YH, Lee YK. Oral absorption mechanism and anti-angiogenesis effect of taurocholic acid-linked heparin-docetaxel conjugates. J Control Release. 2014;177:64–73. doi:10.1016/j.jconrel.2013.12.034.24269968
   PubMedGoogle Scholar
• Arzani G, Haeri A, Daeihamed M, Bakhtiari-Kaboutaraki H, Dadashzadeh S. Niosomal carriers enhance oral bioavailability of carvedilol: effects of bile salt-enriched vesicles and carrier surface charge. Int J Nanomedicine. 2015;104:797–813. doi:10.2147/IJN.S84703
   Web of Science ®Google Scholar
• Li Y, Zhu C. Mechanism of hepatic targeting via oral administration of DSPE-PEG-cholic acid-modified nanoliposomes. Int J Nanomedicine. 2017;12:1673–1684. doi:10.2147/IJN.S125047.
   PubMed Web of Science ®Google Scholar
• Fan W, Xia D, Zhu Q, et al. Functional nanoparticles exploit the bile acid pathway to overcome multiple barriers of the intestinal epithelium for oral insulin delivery. Biomaterials. 2018;151:13–23. doi:10.1016/j.biomaterials.2017.10.022.
   PubMed Web of Science ®Google Scholar
• Kim KS, Suzuki K, Cho H, Youn YS, Bae YH. Oral nanoparticles exhibit specific high-efficiency intestinal uptake and lymphatic transport. ACS Nano. 2018;12(9):8893–8900. doi:10.1021/acsnano.8b0431530088412
   PubMedGoogle Scholar
• Gou J, Liang Y, Miao L, et al. The promoting effect of enteric materials on the oral absorption of larotaxel-loaded polymer-lipid hybrid nanoparticles. Eur J Pharm Sci. 2018;124:288–294. doi:10.1016/j.ejps.2018.09.002.
   PubMed Web of Science ®Google Scholar
• Deng W, Wang H, Wu B, Zhang X. Selenium-layered nanoparticles serving for oral delivery of phytomedicines with hypoglycemic activity to synergistically potentiate the antidiabetic effect. Acta Pharm Sin B. 2019;9(1):74–86. doi:10.1016/j.apsb.2018.09.00930766779
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhang T, Ye Y, et al. Phospholipid-stabilized mesoporous carbon nanospheres as versatile carriers for systemic delivery of amphiphobic SNX-2112 (a Hsp90 inhibitor) with enhanced antitumor effect. Eur J Pharm Biopharm. 2015;94:30–41. doi:10.1016/j.ejpb.2015.04.023.
   PubMed Web of Science ®Google Scholar
• Natoli M, Leoni BD, D’Agnano I, Zucco F, Felsani A. Good Caco-2 cell culture practices. Toxicol In Vitro. 2012;26(8):1243–1246. doi:10.1016/j.tiv.2012.03.00922465559
   PubMed Web of Science ®Google Scholar
• Zhang X, Chen G, Zhang T, Ma Z, Wu B. Effects of PEGylated lipid nanoparticles on the oral absorption of one BCS II drug: a mechanistic investigation. Int J Nanomedicine. 2014;9:5503–5514. doi: 10.2147/IJN.S73340.
   PubMed Web of Science ®Google Scholar
• Ana R, Mendes M, Sousa J, et al. Rethinking carbamazepine oral delivery using polymer-lipid hybrid nanoparticles. Int J Pharm. 2019;554:352–365. doi:10.1016/j.ijpharm.2018.11.028.
   PubMedGoogle Scholar
• Hallan SS, Kaur V, Jain V, Mishra N. Development and characterization of polymer lipid hybrid nanoparticles for oral delivery of LMWH. Artif Cells Nanomed Biotechnol. 2017;45(8):1631–1639. doi:10.1080/21691401.2016.127692028071140
   PubMed Web of Science ®Google Scholar
• Ran F, Lei W, Cui Y, et al. Size effect on oral absorption in polymer-functionalized mesoporous carbon nanoparticles. J Colloid Interface Sci. 2018;511:57–66. doi:10.1016/j.jcis.2017.09.088.
   Google Scholar
• Zhang LJ, Wu B, Zhou W, et al. Two-component reduction-sensitive lipid-polymer hybrid nanoparticles for triggered drug release and enhanced in vitro and in vivo anti-tumor efficacy. Biomater Sci. 2016;5(1):98–110. doi:10.1039/c6bm00662k27841378
   PubMedGoogle Scholar
• Zhang L, Zhu D, Dong X, et al. Folate-modified lipid-polymer hybrid nanoparticles for targeted paclitaxel delivery. Int J Nanomedicine. 2015;10:2101–2114. doi:10.2147/IJN.S77667.
   PubMed Web of Science ®Google Scholar
• Zhu C, Gong S, Ding J, et al. Supersaturated polymeric micelles for oral silybin delivery: the role of the Soluplus-PVPVA complex. Acta Pharm Sin B. 2019;9(1):107–117. doi:10.1016/j.apsb.2018.09.00430766782
   PubMedGoogle Scholar
• Rajabi M, Mousa SA. Lipid nanoparticles and their application in nanomedicine. Curr Pharm Biotechnol. 2016;17(8):662–672.27087491
   PubMed Web of Science ®Google Scholar
• Joyce P, Prestidge CA. Synergistic effect of PLGA nanoparticles and submicron triglyceride droplets in enhancing the intestinal solubilisation of a lipophilic weak base. Eur J Pharm Sci. 2018;118:40–48. doi:10.1016/j.ejps.2018.03.018.
   Web of Science ®Google Scholar
• Wang K, Qi J, Weng T, et al. Enhancement of oral bioavailability of cyclosporine A: comparison of various nanoscale drug-delivery systems. Int J Nanomedicine. 2014;9:4991–4999. doi:10.2147/IJN.S72560.
   PubMed Web of Science ®Google Scholar
• Chalet C, Rubbens J, Tack J, Duchateau GS, Augustijns P. Intestinal disposition of quercetin and its phase-II metabolites after oral administration in healthy volunteers. J Pharm Pharmacol. 2018;70(8):1002–1008. doi:10.1111/jphp.1292929761870
   PubMedGoogle Scholar
• Alakhova DY, Zhao Y, Li S, Kabanov AV. Effect of doxorubicin/pluronic SP1049C on tumorigenicity, aggressiveness, DNA methylation and stem cell markers in murine leukemia. PLoS One. 2013;8(8):e72238–e72238. doi:10.1371/journal.pone.007223823977261
   PubMedGoogle Scholar
• Russo M, Milito A, Spagnuolo C, et al. CK2 and PI3K are direct molecular targets of quercetin in chronic lymphocytic leukaemia. Oncotarget. 2017;8(26):42571–42587. doi:10.18632/oncotarget.1724628489572
   PubMedGoogle Scholar
• Chen X, Dong XS, Gao HY, et al. Suppression of HSP27 increases the antitumor effects of quercetin in human leukemia U937 cells. Mol Med Rep. 2016;13(1):689–696. doi:10.3892/mmr.2015.460026648539
   PubMed Web of Science ®Google Scholar
• Alvarez MC, Maso V, Torello CO, Ferro KP, Saad STO. The polyphenol quercetin induces cell death in leukemia by targeting epigenetic regulators of pro-apoptotic genes. Clin Epigenetics. 2018;10(1):139. doi:10.1186/s13148-018-0563-330409182
   PubMedGoogle Scholar